Alzheimer's disease

Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug
Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug
Fierce Biotech
Eli Lilly
AC Immune
Alzheimer's disease
tau
Flag link:
Eisai, UCL to launch phase I trials of E2814 for Alzheimer’s disease
Eisai, UCL to launch phase I trials of E2814 for Alzheimer’s disease
Pharmaceutical Business Review
Eisai
Alzheimer's disease
E2814
clinical trials
University College London
Flag link:
Finding of dementia genes could speed drug discovery in Alzheimer’s and other brain disorders
Finding of dementia genes could speed drug discovery in Alzheimer’s and other brain disorders
Fierce Biotech
UCLA
Alzheimer's disease
dementia
drug discovery
Flag link:
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
CP Wire
biotech
Alzheimer's disease
NASH
RNA
gene therapy
immuno-oncology
orphan diseases
Flag link:
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
Alzheimer's disease
NASH
RNA
gene therapy
immuno-oncology
orphan diseases
Flag link:
UT Researchers Discover Alzheimer's Vaccine, Hope To Test In Humans Soon
UT Researchers Discover Alzheimer's Vaccine, Hope To Test In Humans Soon
Forbes
Alzheimer's disease
R&D
vaccines
University of Texas
Flag link:
AbbVie enlists protein degradation experts at Mission for a new bet on Alzheimer's, Parkinson's
AbbVie enlists protein degradation experts at Mission for a new bet on Alzheimer's, Parkinson's
Endpoints
targeted protein degradation
AbbVie
Mission Therapeutics
Alzheimer's disease
Parkinson's Disease
Flag link:
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
EP Vantage
Eli Lilly
drug development
Alzheimer's disease
BACE inhibitors
Flag link:
Eli Lilly sweeps the rest of the BACE work out of the pipeline following their latest major setback on Alzheimer’s
Eli Lilly sweeps the rest of the BACE work out of the pipeline following their latest major setback on Alzheimer’s
Endpoints
Eli Lilly
Alzheimer's disease
BACE inhibitors
Flag link:
New prize offers $2 million for finding key to Alzheimer’s in past research
New prize offers $2 million for finding key to Alzheimer’s in past research
Stat
Alzheimer's disease
R&D
drug development
Flag link:
Sanofi Pledges $125M to Denali in Pact for Neuro, Inflammation Drugs
Sanofi Pledges $125M to Denali in Pact for Neuro, Inflammation Drugs
Xconomy
Sanofi
Denali Therapeutics
inflammation
Alzheimer's disease
R&D
Flag link:
How an outsider in Alzheimer’s research bucked the prevailing theory — and clawed for validation
How an outsider in Alzheimer’s research bucked the prevailing theory — and clawed for validation
Stat
R&D
Alzheimer's disease
Flag link:
Neuralstem Rises on Publication of Alzheimer’s Stem Cell Therapy Data
Neuralstem Rises on Publication of Alzheimer’s Stem Cell Therapy Data
CP Wire
Neuralstem
NSI-532.IGF1
Alzheimer's disease
Flag link:
Biogen’s ‘positive’ Alzheimer’s trial has a problem with small numbers
Biogen’s ‘positive’ Alzheimer’s trial has a problem with small numbers
Stat
Biogen
Eisai
BAN2401
Alzheimer's disease
Flag link:
Neuralstem Rises on Publication of Alzheimer’s Stem Cell Therapy Data
Neuralstem
NSI-532.IGF1
Alzheimer's disease
Flag link:
Amgen, Novartis and Banner Alzheimer's Institute Team on 2 Alzheimer's Prevention Trials
Amgen, Novartis and Banner Alzheimer's Institute Team on 2 Alzheimer's Prevention Trials
BioSpace
Amgen
Novartis
Alzheimer's disease
preventative medicine
Flag link:
Tetra Discovery Partners Receives New Patent on Alzheimer's Candidate
Tetra Discovery Partners Receives New Patent on Alzheimer's Candidate
CP Wire
Tetra Discovery Partners
BPN 14770
Alzheimer's disease
dementia
Flag link:
Tetra Discovery Partners Receives New Patent on Alzheimer's Candidate
Tetra Discovery Partners
BPN 14770
Alzheimer's disease
Flag link:
Ionis, Rockefeller team find peripheral blood target for Alzheimer's
Ionis, Rockefeller team find peripheral blood target for Alzheimer's
BioCentury
Ionis Pharmaceuticals
Rockefeller University
Alzheimer's disease
drug development
Flag link:
Senolytic Therapies Seem To Stop Alzheimer's Disease 'In Its Tracks'
Senolytic Therapies Seem To Stop Alzheimer's Disease 'In Its Tracks'
Forbes
Alzheimer's disease
senolytic therapies
Flag link:

Pages